Construction and Validation of a Novel Ferroptosis-related Prognostic Signature for Lung Adenocarcinoma

Overview

Journal Transl Lung Cancer Res

Date 2023 Sep 11

PMID 37691861

Authors

Li Yang

Xinxin Fan

Chao Zhou

Ziqi Wang

Zelong Cui

Xuan Wu

Zhiwei Xu

Jia Yang

Xiaoju Zhang

Affiliations

Soon will be listed here.

Abstract

Background: Lung cancer has the highest prevalence and mortality of all cancers, and lung adenocarcinoma (LUAD) occupies the largest proportion of lung cancers. Herein, this study is aimed at constructing a ferroptosis-related prognostic signature for LUAD and conducting functional analysis based on the signature, highlighting the importance of ferroptosis in LUAD.

Methods: We employed RNA-sequencing (RNA-seq) and clinical data from The Cancer Genome Atlas (TCGA) database. Univariate Cox regression, Least Absolute Shrinkage and Selection Operator (LASSO) regression analysis were conducted to build the ferroptosis-related genes (FRGs) prognostic signature. The efficacy of this FRG signature was further analyzed with Kaplan-Meier (KM) plot, multivariate Cox regression, and the receiver operating characteristic (ROC) curves. Enrichment analysis was used to evaluate key pathways. The expression of immunomodulators, immune infiltration status, and drug sensitivity correlation were explored to predict the response to various therapies. The expression of FRGs was validated in LUAD samples with western blot (WB) and immunohistochemistry (IHC) staining. Cell viability assay and lipid peroxidation detection were measured after small interfering RNA (siRNA) knockdown of two FRGs in lung cancer cell lines.

Results: A seven-gene signature was constructed and used to divide LUAD patients into high- and low-risk groups. High-risk patients were notably related to shorter overall survival (OS), and multivariate Cox regression demonstrated that our signature was an independent predictor of OS. ROC curve analysis presented a maximum area under the curve (AUC) value of 0.740 for the experimental cohort and 0.705 for the validation cohort. The low-risk group showed higher levels of plasma cell infiltration and higher expression of programmed cell death protein 1 () and cytotoxic T-lymphocyte-associated protein 4 (). Ferroptosis inducers such as talazoparib or cisplatin had lower IC50 values in the high-risk group, while navitoclax (BCL-2 gene family inhibition and apoptosis inducer) had higher IC50 values in the high-risk group. Additionally, peroxiredoxin-6 (PRDX6) and acyl-CoA synthetase long chain family member 3 (ACSL3) were upregulated in LUAD tissues. Lipid peroxide assay showed that silencing or promoted lipid peroxidation and ferroptosis in lung cancer cells.

Conclusions: Our novel ferroptosis-related signature shows potential clinical and functional importance in LUAD patients, and further research on ferroptosis as a therapeutic target in LUAD is warranted.

Citing Articles

Tumoral Malignancy Decreases Coupled with Higher ROS and Lipid Peroxidation in HCT116 Colon Cancer Cells upon Loss of PRDX6.

Lagal D, Montes-Osuna A, Ortiz-Olivencia A, Arribas-Parejas C, Ortiz-Alcantara A, Pescuezo-Castillo C Antioxidants (Basel). 2024; 13(7).

PMID: 39061949 PMC: 11274330. DOI: 10.3390/antiox13070881.

Antioxidant Systems as Modulators of Ferroptosis: Focus on Transcription Factors.

Punziano C, Trombetti S, Cesaro E, Grosso M, Faraonio R Antioxidants (Basel). 2024; 13(3).

PMID: 38539832 PMC: 10967371. DOI: 10.3390/antiox13030298.

Metabolism-regulated ferroptosis in cancer progression and therapy.

Ye L, Wen X, Qin J, Zhang X, Wang Y, Wang Z Cell Death Dis. 2024; 15(3):196.

PMID: 38459004 PMC: 10923903. DOI: 10.1038/s41419-024-06584-y.

References

Fisher A, Vasquez-Medina J, Dodia C, Sorokina E, Tao J, Feinstein S . Peroxiredoxin 6 phospholipid hydroperoxidase activity in the repair of peroxidized cell membranes. Redox Biol. 2017; 14:41-46. PMC: 5581854. DOI: 10.1016/j.redox.2017.08.008. View

Rhee S, Chae H, Kim K . Peroxiredoxins: a historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. Free Radic Biol Med. 2005; 38(12):1543-52. DOI: 10.1016/j.freeradbiomed.2005.02.026. View

Zhou N, Bao J . FerrDb: a manually curated resource for regulators and markers of ferroptosis and ferroptosis-disease associations. Database (Oxford). 2020; 2020. PMC: 7100629. DOI: 10.1093/database/baaa021. View

Patil N, Nabet B, Muller S, Koeppen H, Zou W, Giltnane J . Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer. Cancer Cell. 2022; 40(3):289-300.e4. DOI: 10.1016/j.ccell.2022.02.002. View

Liu Y, Ouyang L, Mao C, Chen Y, Li T, Liu N . PCDHB14 promotes ferroptosis and is a novel tumor suppressor in hepatocellular carcinoma. Oncogene. 2022; 41(27):3570-3583. DOI: 10.1038/s41388-022-02370-2. View

Jiang T, Zhou B, Li Y, Yang Q, Tu K, Li L . ALOX12B promotes carcinogenesis in cervical cancer by regulating the PI3K/ERK1 signaling pathway. Oncol Lett. 2020; 20(2):1360-1368. PMC: 7377187. DOI: 10.3892/ol.2020.11641. View

Kim R, Hashimoto A, Markosyan N, Tyurin V, Tyurina Y, Kar G . Ferroptosis of tumour neutrophils causes immune suppression in cancer. Nature. 2022; 612(7939):338-346. PMC: 9875862. DOI: 10.1038/s41586-022-05443-0. View

Chan J, Quintanal-Villalonga A, Gao V, Xie Y, Allaj V, Chaudhary O . Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer. Cancer Cell. 2021; 39(11):1479-1496.e18. PMC: 8628860. DOI: 10.1016/j.ccell.2021.09.008. View

Howlader N, Forjaz G, Mooradian M, Meza R, Kong C, Cronin K . The Effect of Advances in Lung-Cancer Treatment on Population Mortality. N Engl J Med. 2020; 383(7):640-649. PMC: 8577315. DOI: 10.1056/NEJMoa1916623. View

10.

Doll S, Proneth B, Tyurina Y, Panzilius E, Kobayashi S, Ingold I . ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol. 2016; 13(1):91-98. PMC: 5610546. DOI: 10.1038/nchembio.2239. View

11.

Lei G, Zhang Y, Koppula P, Liu X, Zhang J, Lin S . The role of ferroptosis in ionizing radiation-induced cell death and tumor suppression. Cell Res. 2020; 30(2):146-162. PMC: 7015061. DOI: 10.1038/s41422-019-0263-3. View

12.

Liu L, Li H, Wang J, Zhang J, Liang X, Guo W . Leveraging macrophages for cancer theranostics. Adv Drug Deliv Rev. 2022; 183:114136. DOI: 10.1016/j.addr.2022.114136. View

13.

Do Van B, Gouel F, Jonneaux A, Timmerman K, Gele P, Petrault M . Ferroptosis, a newly characterized form of cell death in Parkinson's disease that is regulated by PKC. Neurobiol Dis. 2016; 94:169-78. DOI: 10.1016/j.nbd.2016.05.011. View

14.

Newman A, Liu C, Green M, Gentles A, Feng W, Xu Y . Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015; 12(5):453-7. PMC: 4739640. DOI: 10.1038/nmeth.3337. View

15.

Chen X, Li J, Kang R, Klionsky D, Tang D . Ferroptosis: machinery and regulation. Autophagy. 2020; 17(9):2054-2081. PMC: 8496712. DOI: 10.1080/15548627.2020.1810918. View

16.

Dierge E, Debock E, Guilbaud C, Corbet C, Mignolet E, Mignard L . Peroxidation of n-3 and n-6 polyunsaturated fatty acids in the acidic tumor environment leads to ferroptosis-mediated anticancer effects. Cell Metab. 2021; 33(8):1701-1715.e5. DOI: 10.1016/j.cmet.2021.05.016. View

17.

Kumar R, Coronel L, Somalanka B, Raju A, Aning O, An O . Mitochondrial uncoupling reveals a novel therapeutic opportunity for p53-defective cancers. Nat Commun. 2018; 9(1):3931. PMC: 6158291. DOI: 10.1038/s41467-018-05805-1. View

18.

Yang L, Cao L, Zhang X, Chu B . Targeting ferroptosis as a vulnerability in pulmonary diseases. Cell Death Dis. 2022; 13(7):649. PMC: 9315842. DOI: 10.1038/s41419-022-05070-7. View

19.

Jiang X, Stockwell B, Conrad M . Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 2021; 22(4):266-282. PMC: 8142022. DOI: 10.1038/s41580-020-00324-8. View

20.

Thai A, Solomon B, Sequist L, Gainor J, Heist R . Lung cancer. Lancet. 2021; 398(10299):535-554. DOI: 10.1016/S0140-6736(21)00312-3. View